

Effect of Dopamine D₃ Antagonists on PPI in DBA/2J Mice or PPI Deficit Induced by Neonatal Ventral Hippocampal Lesions in Rats

Min Zhang^{*1}, Michael E Ballard¹, Kathy L Kohlhaas¹, Kaitlin E Browman¹, Ana-Lucia Jongen-Rêlo², Liliame V Unger², Gerard B Fox¹, Gerhard Gross², Michael W Decker¹, Karla U Drescher² and Lynne E Rueter¹

¹Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA;

²Abbott GmbH & Co KG, CNS Pharmacology, Ludwigshafen, Germany

Schizophrenic patients typically exhibit impairment of sensorimotor gating, which can be modeled in animal models such as the test of prepulse inhibition of startle response (PPI) in rodents. It has been found that antipsychotics enhanced PPI in DBA mice and reversed the PPI deficit induced by neonatal ventral hippocampal (NVH) lesions in rats. However, the relative involvement of D₃ and D₂ receptors in these effects is unknown since all antipsychotics are D₂/D₃ antagonists with limited binding preference at D₂ receptors. Therefore, in the current study, we investigated the influence of several dopamine antagonists with higher selectivity at D₃ vs D₂ receptors on PPI in DBA/2J mice and in NVH-lesioned rats. The PPI in DBA/2J mice was enhanced by the nonselective D₂/D₃ antagonists, haloperidol at 0.3–3 mg/kg, or risperidone at 0.3–1 mg/kg, while PPI-enhancing effects were observed after the administration of higher doses of the preferential D₃/D₂ antagonist, BP 897 at 8 mg/kg, and the selective D₃ antagonists, SB 277011 at 30 mg/kg and A-437203 at 30 mg/kg. No effect was observed following the treatment with the selective D₃ antagonist, AVE 5997 up to 30 mg/kg. The PPI deficits induced by NVH lesions were reversed by haloperidol but not by the more selective D₃ antagonists, A-437203 and AVE 5997. BP 897 enhanced PPI nonselectivity, that is, in both lesioned and nonlesioned rats. In summary, the present study indicates that PPI-enhancing effects induced by antipsychotics in DBA/2J mice and in NVH-lesioned rats are unlikely to be mediated by D₃ receptors.

Neuropsychopharmacology (2006) 31, 1382–1392. doi:10.1038/sj.npp.1300985; published online 14 December 2005

Keywords: prepulse inhibition; D₂ receptor; D₃ receptor; schizophrenia; antipsychotics; neurodevelopmental model

INTRODUCTION

The discovery of the existence of dopamine subtypes, D₂, D₃ and D₄ receptor in the D₂-like receptor family (Giros *et al*, 1990; Mills *et al*, 1993), has evoked great interest in developing new antipsychotic agents specifically targeting D₃ and D₄ receptor subtypes with the desire to limit the presumed D₂ receptor-mediated side effects. The clinical significance of D₄ antagonists has come into question after clinical trials showed the lack of antipsychotic activity with D₄ receptor antagonists (Corrigan *et al*, 2004; Kramer *et al*, 1997). The rationale behind the development of compounds interacting with D₃ receptor remains intriguing according to preclinical and clinical data. Firstly, all antipsychotics are

D₂/D₃ antagonists with limited binding preferences at D₂ receptor (Leysen *et al*, 1993; Schwartz *et al*, 2000; Seeman and Talerico, 1998). Secondly, D₃ receptors have been implicated in behavioral sensitization, which could be a potential contributor to the pathogenesis of schizophrenia (Glenthøj and Hemmingsen, 1997; Guillin *et al*, 2001; Lieberman *et al*, 1997; Pilla *et al*, 1999; Richtand *et al*, 2001). Indeed, schizophrenic patients showed exacerbated psychotic symptoms to the administration of psychostimulants at low doses, which did not produce psychotic symptoms in healthy subjects (Janowsky and Davis, 1976; Lieberman *et al*, 1987). Thirdly, increased expression of D₃ receptors was observed in the post-mortem brains of unmedicated schizophrenic patients and the expression was normal in patients treated with antipsychotics (Gurevich *et al*, 1997). Fourthly, the D₃ receptor is predominantly expressed in limbic areas such as shell of the nucleus accumbens, olfactory tubercle, amygdala, and cortical structures important for emotional, cognitive, and motivational processes, and is scarce in side effect-related regions such as striatum and pituitary (Diaz *et al*, 1995; Gurevich and Joyce, 1999). Indeed, accumulating evidence

*Correspondence: Dr M Zhang, Neuroscience Research, Abbott Laboratories, AP9, R4N5, 100 Abbott Park, Abbott Park, IL 60064-6115, USA, Tel: +1 847 938 1016, Fax: +1 847 938 0072, E-mail: min.zhang@abbott.com

Received 12 May 2005; revised 30 September 2005; accepted 4 October 2005

Online publication: 27 October 2005 at <http://www.acnp.org/citations/Npp102705050317/default.pdf>

from combined use of mutant mice and pharmacological approaches supports the notion that it is probably D₂ receptor, but not D₃ receptor, that contributes to the induction of the secondary negative symptoms, adverse cognitive effects, extrapyramidal symptoms, and hyperprolactinemia (Ballard *et al*, 2003; Browman *et al*, 2003; Depoortere, 1999; Millan *et al*, 2004).

In preclinical studies of schizophrenia, animal models have been used to model certain aspects of dysfunctions associated with the disease. For example, schizophrenic patients showed impairments in sensorimotor gating (Braff *et al*, 1978, 2001, 1992), probably a reflection of the disrupted information filtering mechanism contributing to overloading irrelevant stimuli in the cortical regions and subsequently causing confusion, hallucination, and attentional/cognitive deficits in the patients (Carlsson *et al*, 1997; McGhie and Chapman, 1961). One way to assess impaired sensorimotor gating is to measure prepulse inhibition (PPI) of the startle reflex, an operational measure of sensorimotor gating in which the involuntary startle reflex is reduced when a startling stimulus is preceded by a weak acoustic stimulus. Consistent with DA-, glutamate- and serotonin-based hypotheses of schizophrenia, PPI in rats can be disrupted by direct or indirect dopamine agonists, NMDA receptor blockers and 5-HT_{2A} agonists (Mansbach and Geyer, 1989; Mansbach *et al*, 1988; Sipes and Geyer, 1994; Swerdlow and Geyer, 1993; Swerdlow *et al*, 1991; Varty and Higgins, 1998). The reversal of these pharmacologically induced PPI deficits has been considered to indicate antipsychotic potential. However, these pharmacological models are tied to a specific mechanism and may thus be limited for detecting novel mechanisms of action. Recently, it has been suggested that the increase of PPI responding in DBA/2J mice displaying naturally occurring low PPI responses compared to other mouse strains may represent a more attractive animal model for assessing novel antipsychotic mechanisms (Browman *et al*, 2004; Olivier *et al*, 2001).

Another recently developed nonpharmacological model, which also exhibits a fair degree of validity to several aspects of schizophrenia, is the 'neonatal ventral hippocampal (NVH) lesion-induced deficits' model proposed by Lipska and co-workers as offering a valid simulation of psychosis disorders (Lipska *et al*, 2002, 1993; Lipska and Weinberger, 2000). Indeed, NVH-lesioned rats showed behavioral deficits resembling several aspects of schizophrenia. For instance, NVH-lesioned rats showed hyperactivity, PPI deficits, disruption of social interaction, and cognitive deficits (Becker and Grecksch, 2000; Becker *et al*, 1999; Lipska *et al*, 2002, 1995; Sams-Dodd *et al*, 1997), resembling positive, negative, and cognitive symptoms of schizophrenia, respectively. The onset of the schizophrenic symptoms typically appears in early adulthood, and the NVH lesion-induced behavioral abnormality in rats also appeared only after puberty (Lipska *et al*, 1993, 1995). Furthermore, in line with the DA and glutamate hypothesis of schizophrenia, NVH-lesioned rats exhibited exacerbated responses to dopamine direct/indirect agonists and NMDA antagonists, suggesting intrinsic dopaminergic and glutamatergic dysfunctions in these rats (Al-Amin *et al*, 2000; Lipska *et al*, 1993, 1995). As schizophrenic patients whose symptoms could be precipitated by stressful life events

(Howes *et al*, 2004), the lesioned rats also exhibited hypersensitivity to stress (Lipska *et al*, 1993). Finally, some of the behavioral deficits observed in NVH-lesioned rats, such as PPI deficits, were reversible by antipsychotics (Le Pen and Moreau, 2002; Rueter *et al*, 2004).

As mentioned above, antipsychotics have been shown to increase PPI in DBA/2J mice and in NVH-lesioned rats. Since these antipsychotics in general are nonselective at D₂ and D₃ receptors (as shown in Table 1), it was of interest to determine whether D₃ receptors contribute to the efficacy on normalizing PPI functions in these models. Therefore, in the current study we investigated several dopamine antagonists with higher selectivity at D₃ receptors vs D₂ receptors (see Table 1) in these two animal models: BP 897 (Pilla *et al*, 1999; Wicke and Garcia-Ladona, 2001; Wood *et al*, 2000), SB 277011 (Ballard *et al*, 2003; Reavill *et al*, 2000), A-437203 (Gross *et al*, 1997; Unger *et al*, 2002) and AVE 5997 (Kongsamut, 2003). Unlike SB 277011, A-437203 and AVE 5997, BP 897 is less selective at D₃ and its intrinsic activity has been controversial. It has been characterized as a partial D₃ agonist and a D₃ antagonist depending on the assay used. For instance, BP 897, as a partial agonist, was able to inhibit forskolin-induced cAMP accumulation and induce mitogenesis in NG-108-15 cells transfected with human dopamine D₃ receptors (Pilla *et al*, 1999; Pilon *et al*, 1994). However, it was unable to increase GTPγS binding in human (h) D₃/CHO cells and potently inhibited the increase induced by dopamine, a reflection of antagonistic properties (Wicke and Garcia-Ladona, 2001). In support of its intrinsic activity as a D₃ antagonist, BP 897 did not affect neuronal firing rate in substantia nigra after acute treatment, while in the same assay D₃/D₂ agonists such as PD128907 and quinpirole showed dose-dependent inhibitory effects, which could be blocked by BP 897 (Wicke and Garcia-Ladona, 2001). Furthermore, as potent D₃ antagonists such as SB 277011 (Vorel *et al*, 2002), BP 897 has been shown to reduce cocaine-seeking behavior in rats (Garcia-Ladona and Cox, 2003; Pilla *et al*, 1999). The doses of D₃ antagonists have been proven to be bioactive by published pharmacological studies. For instance, BP 897 at 1 mg/kg reduced cocaine-seeking behavior in rats (Garcia-Ladona and Cox, 2003); SB 277011 at the dose of 3 mg/kg significantly reversed PPI deficit induced by social isolation (Reavill *et al*, 2000); A-437203 significantly reversed

Table 1 Drug Affinities (nM) of Antagonists to Cloned Human D₂ and D₃ Receptors

Compounds	K _i D ₂ (nM)	K _i D ₃ (nM)	Selectivity D ₃ /D ₂
Haloperidol ^a	0.3–0.6	3	≈0.1
Risperidone ^a	1–4	5–11	≈1
BP 897 ^b	61	0.92	66.3
SB-277011 ^c	1047	11.2	93.5
A-437203 ^d	351.00	2.92	120.2
AVE 5997 ^e	1470	5.1	288.2

^aJoyce (2001).

^bPilla *et al* (1999).

^cReavill *et al* (2000).

^dUnger *et al* (2002).

^eKongsamut (2003).

PD-128907-induced social interaction deficit in rats at the doses of 1–4.64 mg/kg (Drescher *et al*, 2002); AVE 5997 antagonized MK-801-induced hyperactivity with an ED₅₀ of about 0.1 mg/kg (Kongsamut, 2003).

MATERIALS AND METHODS

Animals

For mouse PPI studies male 4-week-old DBA/2J mice were obtained from Jackson Laboratories (USA) and housed in climate-controlled animal facilities under 12-h light–dark cycle (lights on at 0600). The methodology of the study in NVH-lesioned rats was as described previously (Rueter *et al*, 2004). Pregnant female Sprague–Dawley rats (16 day) were purchased from Charles River (USA). Since birth, mother and litter size can influence the physical and behavioral development of pups, multiple measures were taken to control for these factors. Litters were culled to all male pups on postnatal day (PD) 4 with cross fostering in order to control for differences between birth mothers and to equate litter size, which allows each pup equal access to feeding. Surgery was performed on PD 7 with pups from each dam being assigned to the lesioned and nonlesioned groups. Pups were immediately returned to the dams following recovery, again employing cross fostering to equate litter size. Each dam subsequently raised a litter of lesioned or nonlesioned pups. At PD 28, pups were weaned and housed three per cage in a reversed light cycle (lights off 0800, lights on 2100). Animals had access to food and water ad libitum. Testing began after the rats were 8 weeks old. All experiments were conducted in accordance with Abbott Animal Care and Use Committee and National Institutes of Health Guide for Care and Use of Laboratory Animals guidelines in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.

Surgical Procedures

As previously described (Rueter *et al*, 2004), pups were anesthetized by hypothermia on ice for 10–15 min. Pups were placed in a stereotaxic device with modified ear bars that had rubber cups on the tips that gently held the head in place. An incision was made through the skin of the skull, and the skin was retracted in order to expose the skull. Bilateral injections were made using needle tips cut from 10 µl Hamilton syringes spaced 7 mm apart on the carrier. The stereotaxic coordinates from bregma were AP-3.0, L-3.5, V-5.0. Ibotenic acid (2.5 µg) was infused over 2 min and the cannulae were left in place for a subsequent 2 min. The skin was sutured using VetBond (Webster Veterinary Supply, Sterling, MA, USA) and pups were immediately placed in a heated recovery area. Pups were constantly monitored and periodically stimulated using gentle stroking until they fully recovered. Following recovery, pups were immediately returned to the dams.

PPI Assay

In all of the behavioral tests, the animals were brought to a holding room adjacent to the testing room at least 60 min prior to the drug administration.

DBA/2J mice were tested in their light phase in Hamilton Kinder PPI equipment (SM 100 version 4.1, Poway, CA, USA) and the rats were tested in their dark phase in San Diego Instruments equipment (SRLAB, San Diego Instruments, San Diego, CA, USA). The animals were given a 5-min acclimation period in the startle chambers during which a 65-decibel (dB) background noise was presented. This background noise remained throughout the entire test. Following the 5-min acclimation period, four successive trials of 40-ms noise bursts at 120 dB were presented. These trials were not included in data analysis. The rats were then exposed to five different types of acoustic stimuli: Pulse Alone (120-dB noise for 40 ms), No Stimulus (no stimulus was presented), and three Prepulse + Pulse with prepulse set at three sound levels of 70, 75 and 80 dB for 20 ms followed by 40-ms pulse at 120 dB. There were 100 ms from the initiation of prepulse to the onset of the pulse. A total of 12 trials under each acoustic stimulus condition were presented with 15-s variable intervals. Finally, the test ended with four trials of 40-ms 120-dB pulse, which were excluded from data analysis. The inclusion of four Pulse Alone trials in the beginning of the experiment were presented to help normalize the responses of the mice, as there is rapid habituation to the startle response seen within the first few trials (Dulawa and Geyer, 2000). The four Pulse Alone trials at the end of the test session are part of the standard lab PPI program and are included to provide a means to assess startle reflex habituation to acoustic stimuli when it is of interest in a study. As we have not seen a differential effect of antipsychotics on habituation within these models (Rueter *et al*, 2004), those eight trials were excluded from data analysis in the current experiments. Percent PPI was calculated as following: $(1 - (\text{startle response to Prepulse} + \text{Pulse}) / (\text{startle response to Pulse Alone})) \times 100$.

Compounds and Doses

Risperidone (ICN Biomedicals Inc., Irvine, CA, USA), ibotenic acid (Sigma Chemical Co., St Louis, MO, USA), and haloperidol (Sigma Chemical Co., St Louis, MO, USA) were purchased from commercial suppliers. SB 277011, BP 897, AVE 5997, and A-437203 were synthesized at Abbott Laboratories (Ludwigshafen, Germany). A-437203 was dissolved in 1 N NaOH and then titrated to a final pH 9–10 with 1 N HCL. The other compounds were dissolved in 1 N HCL or acetic acid and then titrated to a final pH 5–6 with 10 N NaOH. In mouse PPI studies, all solutions were administered intraperitoneally (i.p.) in a volume of 10 ml/kg. In rat PPI studies, the solutions were administered in a volume of 1 or 2 ml/kg dependent upon solubility of the compounds, and the solutions were given i.p. except SB 277011 and haloperidol, which were administered subcutaneously (s.c.). In both mouse and rat studies, risperidone, haloperidol and BP 897 were administered 30 min before the PPI tests, while the other compounds were given 60 min prior to testing. The administration route, pretreatment time and doses were chosen based upon our preliminary studies.

Histological Verification of Lesions

Following the final experiment, rats were deeply anesthetized with pentobarbital (Nembutal; Abbott, Abbott Park,

IL, USA) and transcardially perfused with saline and then 10% formalin. Following sectioning on a cryostat, brain slices were stained with cresyl violet and assessed for the degree of lesion. Figure 1 represents the largest (strips) and smallest (gray) amount of damage found upon histological investigation with animals falling all along the continuum between the two.

Statistical Analysis

In mouse PPI studies, % PPI data were analyzed by a two-way ANOVA with prepulse intensity as repeated measures and treatment as between-subjects factor. If a significant treatment effect and interaction of treatment and prepulse were identified, the % PPI was then analyzed by Fisher's *post hoc* PLSD test to compare group means at each prepulse level. If a significant treatment effect was identified without the presence of significant interaction of treatment and prepulse, % PPI was collapsed across prepulse levels and analyzed by Fisher's PLSD to compare means of treatment groups. Startle responses to pulse alone in the PPI studies were analyzed using one-way ANOVA with treatment as an independent variable, followed by Fisher's PLSD *post hoc* comparison to compare means of treatment groups. Alpha was set at 0.05.

In rat, PPI studies involving NVH lesions, % PPI data were analyzed using a three-way ANOVA (lesion \times drug treatment \times prepulse intensity) with repeated measures on prepulse intensity, followed when appropriate by separate two-way ANOVA or by the Fisher's PLSD. Startle responses

to pulse alone were analyzed by two-way ANOVA (lesion \times treatment) followed by Fisher's PLSD. Alpha was set at 0.05.

RESULTS

Assessing Nonselective and Selective D₃ Antagonists on PPI in DBA/2J Mice

Haloperidol. Two-way ANOVA revealed a significant main effect of treatment on % PPI ($F(3, 35) = 4.014, p < 0.05$) and prepulse intensity ($F(2, 70) = 167.546, p < 0.01$). No significant interaction of treatment and prepulse intensity was observed. Follow-up Fisher's PLSD analysis of treatment effect indicated a significant enhancement of % PPI in mice treated with haloperidol at all of the doses tested ($p < 0.05$ or $p < 0.01$ vs vehicle-treated group, as shown in the left panel of Figure 2a). No significant main effect of treatment on startle was revealed by one-way ANOVA (right panel of Figure 2a).

Risperidone. Two-way ANOVA revealed a significant main effect of treatment on % PPI ($F(3, 32) = 5.039, p < 0.01$) and prepulse intensity ($F(2, 64) = 52.319, p < 0.01$). No significant interaction of treatment and prepulse intensity was observed. Fisher's PLSD analysis of treatment effect indicated a significant enhancement of % PPI in mice treated with risperidone at 0.3 mg/kg and 1 mg/kg ($p < 0.01$ vs vehicle-treated group, as shown in the left panel of Figure 2b). One-way ANOVA revealed a strong trend towards a main effect on startle ($F(3, 32) = 2.829,$




Figure 1 Neonatal hippocampal lesions: the amount of damage to the hippocampus found upon histological investigation of the lesioned animals is noted for the largest lesion found (strips) and the smallest lesion (gray shading). The distance from bregma is denoted along side each slice. The sections are redrawn from the stereotaxic atlas of Paxinos and Watson (1998).




Figure 2 Effect of nonselective D₂/D₃ antagonists, haloperidol, and risperidone, and the preferential D₃ antagonist, BP 897, on PPI in DBA/2J mice. The effects on PPI and startle responses were presented on the left and the right side of the panels, respectively. Haloperidol (panel a, $N = 9-10$ /group) significantly increased PPI at all of the doses tested while eliciting a nonsignificant reduction of startle response to pulse alone. Risperidone (panel b, $N = 9$ /group) significantly increased PPI at 0.3 and 1 mg/kg, BP 897 (panel c, $N = 11-13$ /group), significantly increased PPI at 8 mg/kg whose effect was comparable to its comparator, risperidone, although it did not reduce startle response as risperidone did in the same experiment. * $p < 0.05$ and ** $p < 0.01$, compared to vehicle-treated alone group.

$p = 0.054$) (right panel of Figure 2b). Risperidone at 1 mg/kg was used as a comparator and a positive control in the following studies investigating more selective D₃ antagonists.

BP 897. Two-way ANOVA revealed a significant main effect of treatment on % PPI ($F(5, 66) = 2.936$, $p < 0.05$) and a significant main effect of prepulse intensity ($F(2, 132) = 103.263$, $p < 0.01$). No significant interaction of treatment and prepulse intensity was observed. Fisher's PLSD analysis of treatment effect demonstrated a significant enhancement of % PPI in mice treated with BP 897 at 8 mg/kg and with the comparator, risperidone, with regard to vehicle-treated mice, as shown in the left panel of Figure 2c ($p < 0.05$).

One-way ANOVA revealed a significant main effect of treatment on startle responses to pulse alone ($F(5, 66) = 5.575$, $p < 0.01$) with follow-up Fisher's PLSD demonstrating that the comparator, risperidone, significantly reduced startle responses ($p < 0.01$, vs vehicle-treated group, as shown in the right panel of Figure 2c).

SB 277011. Two-way ANOVA revealed a significant main effect of treatment on % PPI ($F(6, 65) = 3.696$, $p < 0.01$) and a significant main effect of prepulse intensity ($F(2, 130) = 77.677$, $p < 0.01$). No significant interaction of treatment and prepulse intensity was observed. Fisher's PLSD analysis of treatment effect demonstrated a significant enhancement of % PPI in mice treated with SB 277011 at 30 mg/kg, as shown in the left panel of Figure 3a ($p < 0.05$, vs vehicle-treated group). No significant main effect of treatment on startle was revealed by one-way ANOVA, as shown in the right panel of Figure 3a.

A-437203. Two-way ANOVA revealed a significant main effect of treatment on % PPI ($F(4, 74) = 3.465$, $p < 0.05$) and a significant main effect of prepulse intensity ($F(2, 148) = 202.557$, $p < 0.01$). No significant interaction of treatment and prepulse intensity was observed. Fisher's PLSD analysis of treatment effect demonstrated a significant enhancement of % PPI in mice treated with A-437203 at 30 mg/kg and with the comparator, risperidone, as shown in the left panel of Figure 3b ($p < 0.05$ and < 0.01 , respectively). One-way ANOVA revealed a significant main effect of treatment on startle responses to pulse alone ($F(4, 74) = 4.102$, $p < 0.01$) with Fisher's PLSD analysis of treatment effect demonstrating that risperidone significantly reduced startle responses ($p < 0.01$, vs vehicle-treated group), as shown in the right panel of Figure 3b.

AVE 5997. Two-way ANOVA revealed a significant main effect of treatment on % PPI ($F(5, 42) = 3.273$, $p < 0.05$) and prepulse intensity ($F(2, 84) = 134.672$, $p < 0.01$). No significant interaction of treatment and prepulse intensity was observed. Fisher's PLSD analysis of treatment effect showed a significant enhancement of % PPI only following the treatment of the comparator, risperidone ($p < 0.05$, vs vehicle-treated group), but not the treatment of AVE 5997 at any of the doses tested, as shown in the left panel of Figure 3c. A marginal significant main effect of treatment on startle was revealed by one-way ANOVA ($F(5, 42) = 4.402$, $p = 0.086$).

Assessing Nonselective and Selective D₃ Antagonists on PPI Deficits Induced by NVH Lesion

Haloperidol. For the measure of % PPI as shown in the left panel of Figure 4a, three-way ANOVA revealed a significant main effect of treatment ($F(1, 76) = 15.024$, $p < 0.01$), prepulse intensity ($F(2, 152) = 145.414$, $p < 0.01$), and lesion ($F(1, 76) = 31.327$, $p < 0.01$), as well as a significant lesion \times treatment interaction ($F(1, 76) = 4.229$, $p < 0.05$) suggesting that the effect of haloperidol on PPI was different between lesioned and nonlesioned groups. Follow-up Fisher's PLSD indicated that NVH lesion-induced PPI reduction was reversed by haloperidol in lesioned ($p < 0.01$) but not in nonlesioned rats. For the measure of startle responses to




Figure 3 Effect of selective D₃ antagonists, SB 277011, A-437203, and AVE 5997 on PPI in DBA/2J mice. The effects on PPI and startle responses were presented on the left and the right side of the panels, respectively. SB 277011 (panel a, $N=10-11$) and A-437203 (panel b, $N=17-18$ for vehicle- and A-437203-treated groups; $n=8$ for risperidone-treated group) significantly increased PPI at 30 mg/kg, an effect at least comparable to risperidone without affecting startle responses as much as risperidone. However, AVE 5997 (panel c, $N=8$ /group) did not produce a significant effect on PPI or startle response. * $p < 0.05$ and ** $p < 0.01$, compared to vehicle-treated group.

pulse alone as shown in the right panel of Figure 4a, two-way analysis of ANOVA only revealed a significant main effect of treatment ($F(1, 76) = 26.441$, $p < 0.01$), indicating that haloperidol reduced startle independent of surgery condition.

BP 897. For the measure of % PPI as shown in the left panel of Figure 4b, three-way ANOVA revealed a significant main effect of treatment ($F(1, 76) = 4.251$, $p < 0.05$), prepulse intensity ($F(2, 152) = 180.434$, $p < 0.01$), and lesion ($F(1, 76) = 14.991$, $p < 0.01$). No significant interaction of treatment and lesion was found, suggesting that BP 897-induced PPI enhancing effect was not selective for the lesioned group. For the measure of startle responses to




Figure 4 Effect of haloperidol and BP 897 on PPI deficits induced by NVH lesions. Neonatal lesion induced significant PPI deficits. Haloperidol (panel a, $N=20$) significantly enhanced PPI in NVH-lesioned group but not in nonlesioned group. BP 897 (panel b, $N=20$) only produced a significant main effect of treatment on PPI. No significant interaction of treatment and lesion was observed following BP 897 treatment. Both compounds significantly reduced startle response. ** $p < 0.01$, compared to NVH-nonlesioned group receiving vehicle treatment; ## $p < 0.01$, compared to NVH-lesioned group receiving vehicle treatment; & $p < 0.05$ and && $p < 0.01$, significant main effect of treatment on startle response or PPI; @@ $p < 0.01$, significant main effect of lesion on PPI.

pulse alone as shown in the right panel of Figure 4b, two-way analysis of ANOVA only revealed a significant main effect of treatment ($F(1, 76) = 8.159$, $p < 0.05$), indicating that the treatment of BP 897 significantly reduced startle.

A-437203. For the measure of % PPI as shown in the left panel of Figure 5a, three-way ANOVA only revealed a significant main effect of lesion ($F(1, 64) = 16.638$, $p < 0.01$), and prepulse intensity ($F(2, 128) = 155.967$, $p < 0.01$). For the measure of startle responses to pulse alone as shown in the right panel of Figure 5a, two-way analysis of ANOVA only revealed a significant main effect of treatment ($F(2, 64) = 12.632$, $p < 0.01$) indicating that the treatment of A-437203 significantly reduced startle.

AVE-5997. For the measure of % PPI as shown in the left panel of Figure 5b, three-way ANOVA only revealed a significant main effect of lesion ($F(1, 59) = 16.732$, $p < 0.01$), and prepulse intensity ($F(2, 118) = 144.165$, $p < 0.01$). For the measure of startle responses to pulse alone as shown in the right panel of Figure 5b, two-way analysis of ANOVA only revealed a significant main effect of lesion ($F(1, 59) = 4.501$, $p < 0.05$) indicating that lesion induced a significant enhancement of startle.




Figure 5 Effect of A-437203 and AVE 5997 on PPI deficits induced by NVH lesions. A-437203 (panel a, $N = 11-12$) and AVE 5997 (panel b, $N = 9-12$) did not affect PPI in either lesioned or nonlesioned groups. $*p < 0.05$ and $**p < 0.01$, a significant main effect of lesion on PPI or startle response; $\&\&p < 0.01$, a significant main effect of treatment on startle response, indicating that A-437203 significantly affected startle responses.

DISCUSSION

The current study showed that PPI responses in DBA/2J mice exhibiting lower PPI than other mice strains (Paylor and Crawley, 1997) were enhanced by the nonselective D₂/D₃ antagonists, haloperidol, and risperidone, while higher doses were required to make the enhancement by the preferential D₃/D₂ antagonist, BP 897, and the selective D₃ antagonists, SB 277011 and A-437203. No increase of PPI responses in DBA/2J mice was found following the treatment of AVE 5997, another putative selective D₃ antagonist. The PPI deficits induced by NVH lesions were also significantly reversed by haloperidol but not by more selective D₃ antagonists, A-437203 and AVE 5997. Although BP 897 elicited a significant main effect of treatment on PPI, the nonsignificant interaction of treatment and lesion suggested the effect was not selective to the lesioned rats.

Several lines of preclinical evidence have suggested that D₃ antagonists may have antipsychotic potential. For instance, SB 277011 has been demonstrated to reverse PPI deficits induced by social isolation and by the preferential D₃ agonist, PD 128907 (Reavill *et al*, 2000; Zhang *et al*, 2003). Subchronic treatment of SB 277011 preferentially reduced firing rates of DA neurons in ventral tegmental area, a pattern shared by atypical antipsychotics (Ashby *et al*, 2000; Gross *et al*, 1997). Furthermore, a certain degree of interaction of DA and glutamate systems via D₃ receptor has been implicated (Leriche *et al*, 2003). It is also interesting to consider a potential role of D₃ receptor in

schizophrenia from the perspective of its involvement in dopamine sensitization, which has been implicated in the disease (Lieberman *et al*, 1997; Richtand *et al*, 2001).

Schizophrenia is a debilitating disease involving dysfunctions in multiple high-order brain areas and numerous neurobiological substrates. Given the complexity of the symptoms in affective, social, motor, and cognitive/perceptive domains, it is impossible to characterize the disease in one animal model, and thus the animal models developed to understand the pathogenesis and identify novel antipsychotics usually only represent specific dysfunctions of schizophrenic patients (Lipska and Weinberger, 2000). Studying the PPI of startle response in rodents has been an approach to investigate neuropathology of impaired sensorimotor gating in schizophrenic patients. Accumulating evidence has strongly implicated an involvement of the dopaminergic system in sensory motor gating. For instance, PPI in rodents can be disrupted by direct dopamine agonists, such as apomorphine and quinpirole, and indirect agonists such as amphetamine and cocaine (Geyer *et al*, 1990; Mansbach *et al*, 1988; Varty and Higgins, 1998). Furthermore, mice lacking the DA transporter also exhibit profound reduction of PPI accompanied by a robust and life-long increase of DA activity in the brain (Giros *et al*, 1996; Ralph *et al*, 2001). Many studies have also been conducted to investigate the relative involvement of subtypes of DA receptors in modulating PPI. There is a general agreement that D₂-like receptors, rather than D₁ receptors, play an important role in modulation of PPI in rats (Geyer *et al*, 2001), although D₁ receptors may indirectly affect PPI by a synergistic interaction with the D₂-like family (Peng *et al*, 1990; Wan *et al*, 1996a). The reversal of PPI-disruptive effects of D₂-like agonists by antipsychotics strongly implicate the D₂-like receptors in PPI modulation. Since the discovery of the D₃ receptor subtype, efforts have been dedicated to dissect the relative involvement of D₂ and D₃ receptor in modulation of PPI and whether D₃ receptors contribute to the clinical effects of antipsychotics. Findings that preferential D₃ receptor agonists, PD 128907 and 7-OH-DPAT, disrupt PPI of the startle response indicate that the D₃ receptor might play a role in sensorimotor gating (Varty and Higgins, 1998; Zhang *et al*, 2003). However, these behavioral effects are confounded by the fact that none of these agonists are highly selective at D₃ receptors in *in vivo* or *in vitro* functional studies, despite their D₃ selectivity reported in radioligand binding studies (Audinot *et al*, 1998; Pugsley *et al*, 1995; Zapata *et al*, 2001). Although PPI deficits in socially isolated rats were attenuated by the selective D₃ receptor antagonist SB 277011, PPI disruption induced by the D₂ receptor preferring agonist apomorphine was not antagonized by SB 277011 (Reavill *et al*, 2000). In contrast to the ambiguous involvement of D₃ receptors in sensorimotor gating, the role of D₂ receptors has been strongly implicated by the finding that amphetamine-induced PPI disruption was diminished in mice lacking the D₂ but not the D₃ or D₄ receptor (Ralph *et al*, 1999).

The PPI responding in DBA/2J mice has been found to be enhanced by nonselective D₂/D₃ receptor antagonists both in the current and other published studies from several independent laboratories (McCaughan *et al*, 1997; Olivier *et al*, 2001). However, in the current studies, when the

selectivity of dopamine antagonists shifts towards D₃ receptors, higher doses were required to obtain the PPI enhancing effect following the treatment of two selective D₃ antagonists, A-437203 and SB 277011, and no effect was observed with the treatment of AVE 5997, suggesting a less important role of D₃ receptors in modulation of PPI in DBA/2J mice. However, to our knowledge, nothing is known about D₃ receptors in DBA/2J mice such as receptor distribution, density, and intrinsic activity. Indeed, species differences in D₃ receptor distribution have been reported (Diaz *et al*, 2000; Gurevich and Joyce, 1999). Therefore, it is too early to completely rule out a role of D₃ receptors in sensorimotor gating in general based upon the current study in DBA/2J mice.

As previously reported (Lipska *et al*, 1995), we showed in this study that NVH lesions elicited deficits in sensorimotor gating. An enhancement of postsynaptic DA sensitivity in NVH-lesioned rats has been speculated to underlie the effect given that the lesioned rats show exaggerated responses to DA indirect and direct agonists (Lipska *et al*, 1993; Wan and Corbett, 1997), while no change of basal DA and no further enhancement of DA were observed following amphetamine treatment compared to nonlesioned rats (Wan *et al*, 1996b). The supersensitive postsynaptic DA receptors might contribute to the behavioral alternations observed in NVH-lesioned rats such as impaired sensorimotor gating, enhanced activity in a novel environment, and exaggerated response to stress given the proposed role of DA in gating and motor functions as well as in mediating affective responses to stress. In agreement, we showed in the current study that impaired PPI of startle reflex could be reversed by the D₂/D₃ antagonist, haloperidol. It has been previously reported that NVH lesion-induced PPI deficits were reversible by atypical antipsychotics such as risperidone, clozapine, and olanzapine but not by haloperidol (Le Pen and Moreau, 2002). It is unclear what contributed to this discrepancy between laboratories for the response to haloperidol, although it could be a result of a difference in methodology and dosing. For example, haloperidol was given subcutaneously in the current study, while in Le Pen study, haloperidol was given intraperitoneally. It has been suggested that different administration routes may result in a difference in the pattern of behavioral response (Gentry *et al*, 2004). No significant attenuation of PPI deficits in NVH-lesioned rats was observed following more selective D₃ antagonists, A-437203 and AVE 5997, suggesting that selective blockade of D₃ receptor alone is not sufficient to reverse sensorimotor gating deficits elicited by NVH lesions.

In good agreement with the literature, we also showed that antipsychotics such as risperidone reduced startle responses (Le Pen and Moreau, 2002; Olivier *et al*, 2001) when enhancing PPI. This raises a general concern that the effects on PPI might be secondary to their effects on the startle responses. To address this issue, all of the data of vehicle- and 1 mg/kg risperidone-treated mice from the mouse studies of risperidone, BP 897, SB 277011 and AVE-5997 were pooled and then were sorted by startle responses in ascending values (raw data not shown). In order to obtain equal startle magnitude in the vehicle and risperidone groups, the pairs of individuals with risperidone and vehicle treatment listed next to each other were kept for

further analysis. In cases where there were two possible pairs (eg if there was a sequence of vehicle-risperidone-vehicle, risperidone could be paired with the first vehicle and the second vehicle), the pair that had the smaller startle difference between vehicle- and risperidone-treated mice was chosen. This selection resulted in $n = 19$ in water- and risperidone-treated groups, respectively. The remaining mice were excluded. One-way ANOVA revealed (see Figure 6) that there was a significant difference ($p < 0.01$) in % PPI between risperidone- and water-treated mice when their mean values of startle magnitude were equal, suggesting that the effects on PPI responding can be independent of the effects on startle magnitude. A more differentiable effect was observed with haloperidol, which significantly enhanced PPI at 0.3 mg/kg, a dose that only slightly affected basal startle reflex (Figure 2a). Furthermore, haloperidol-induced PPI enhancement did not follow the pattern of its effect on startle reflex. A clearer separation between PPI and startle reflex was demonstrated in rats. For example, A-437203 (Figure 5a) reduced startle responses by more than 50%, while it only slightly increased PPI in both nonlesioned and lesioned rats. There are several lines of evidence supporting the independence of drug effect on PPI and startle reflex. For instance, diazepam significantly reduced startle responses in BALB/cByJ and 129/SvEv without affecting PPI, although it affected PPI and startle response simultaneously in C57 mice (Ouagazzal *et al*, 2001). A study investigating basal acoustic startle response and PPI among several inbred mouse strains showed there was no correlation between the magnitude of basal acoustic startle responses and PPI (Paylor and Crawley, 1997), suggesting differently genetically defined physiological processes are involved in basal acoustic startle and PPI of startle reflex. It is of interest to notice that in DBA/2J mice, D₃ antagonists at a high dose can increase PPI responses without affecting startle reflex as much as their comparator, risperidone. A dissociation expressed in a different way was also observed in NVH studies where some of the selective




Figure 6 All of the data of vehicle- and 1 mg/kg risperidone-treated mice from the mouse studies of risperidone, BP 897, SB 277011 and AVE-5997 were pooled and then the startle magnitude of vehicle- and risperidone-treated individuals were matched (for details, see paragraph 6 in the Discussion) to compare the effect of vehicle and risperidone on % PPI when the startle magnitude was equal. This selection resulted in $n = 19$ in water- and risperidone-treated groups, respectively. One-way ANOVA revealed a significant difference $** (p < 0.01)$ between risperidone- and water-treated mice when their mean values of startle magnitude were equal, suggesting that the effects on PPI responding can be independent of the effects on startle magnitude.

D₃ antagonists significantly reduced startle reflex without significantly improving PPI deficit. These observations provide additional evidence supporting the dissociation of the effect on PPI and that on startle reflex, as well as the idea that different neurobiological processes may underlie gating processes and startle reflex.

In summary, the present study indicates that PPI enhancing effects induced by antipsychotics in DBA/2J mice and in NVH-lesioned rats are less likely to be mediated by blockade of D₃ receptors. As mentioned above, there is evidence from clinical and preclinical studies to support a potential use of D₃ antagonists as antipsychotics. It is likely that D₃ antagonists may possess antipsychotic actions via mechanisms that cannot be reflected by the animal models used in the current study, given that any animal model can only represent certain aspects of a very heterogeneous disease. Whether these models vs other models/theories are ultimately predictive of efficacy will eventually be obtained from clinical trials.

ACKNOWLEDGEMENTS

We thank Dr Anton Bernalov for his valuable contributions to the manuscript and Dr Andreas Haupt, Dr Wilfried Braje, and Dr Dan Plata for their contributions to the compound synthesis.

REFERENCES

- Al-Amin HA, Weinberger DR, Lipska BK (2000). Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus. *Behav Pharmacol* 11: 269–278.
- Ashby Jr CR, Minabe Y, Stemp G, Hagan JJ, Middlemiss DN (2000). Acute and chronic administration of the selective D(3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an *in vivo* electrophysiological study. *J Pharmacol Exp Ther* 294: 1166–1174.
- Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F *et al* (1998). A comparative *in vitro* and *in vivo* pharmacological characterization of the novel dopamine D₃ receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. *J Pharmacol Exp Ther* 287: 187–197.
- Ballard ME, Zhang M, Drescher K, Gross G, Decker MW, Rueter LE (2003). Sucrose consumption and drug-induced helplessness tests: preclinical animal models for assessing drug-induced anhedonia and motivational deficit. 33th Annual Meeting, Society of Neuroscience, New Orleans.
- Becker A, Grecksch G (2000). Social memory is impaired in neonatally ibotenic acid lesioned rats. *Behav Brain Res* 109: 137–140.
- Becker A, Grecksch G, Bernstein HG, Hollt V, Bogerts B (1999). Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. *Psychopharmacology (Berl)* 144: 333–338.
- Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. *Psychophysiology* 15: 339–343.
- Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. *Psychopharmacology (Berl)* 156: 234–258.
- Braff DL, Grillon C, Geyer MA (1992). Gating and habituation of the startle reflex in schizophrenic patients. *Arch Gen Psychiatry* 49: 206–215.
- Browman KE, Briggs AC, Unger LA, Komater VA, Rueter LE, Gross G *et al* (2003). D₂ receptor—but not D₃ receptor—antagonists differentially impair spatial learning in mice. 32th Annual Meeting, Society of Neuroscience, Orlando.
- Browman KE, Komater VA, Curzon P, Rueter LE, Hancock AA, Decker MW *et al* (2004). Enhancement of prepulse inhibition of startle in mice by the H₃ receptor antagonists thioperamide and ciproxifan. *Behav Brain Res* 153: 69–76.
- Carlsson A, Hansson LO, Waters N, Carlsson ML (1997). Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. *Life Sci* 61: 75–94.
- Corrigan MH, Gallen CC, Bonura ML, Merchant KM (2004). Effectiveness of the selective D₄ antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. *Biol Psychiatry* 55: 445–451.
- Depoortere R (1999). Combined use of mutant mice and classical pharmacology to characterise receptor functions: the case of dopamine D₂ and D₃ receptors. *Psychopharmacology (Berl)* 147: 20–21.
- Diaz J, Levesque D, Lammers CH, Griffon N, Martres MP, Schwartz JC *et al* (1995). Phenotypical characterization of neurons expressing the dopamine D₃ receptor in the rat brain. *Neuroscience* 65: 731–745.
- Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC *et al* (2000). Dopamine D₃ receptors expressed by all mesencephalic dopamine neurons. *J Neurosci* 20: 8677–8684.
- Drescher K, Garcia LFJ, Teschendorf HJ, Traut M, Unger L, Wicke KM *et al* (2002). *In vivo* effects of the selective dopamine D₃ receptor antagonist A-437203. 32th Annual Meeting, Society of Neuroscience, Orlando.
- Dulawa SC, Geyer MA (2000). Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. *Neuropharmacology* 39: 2170–2179.
- Garcia-Ladona FJ, Cox BF (2003). BP 897, a selective dopamine D₃ receptor ligand with therapeutic potential for the treatment of cocaine-addiction. *CNS Drug Rev* 9: 141–158.
- Gentry WB, Ghafoor AU, Wessinger WD, Laurenzana EM, Hendrickson HP, Owens SM (2004). Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration. *Pharmacol Biochem Behav* 79: 751–760.
- Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. *Psychopharmacology (Berl)* 156: 117–154.
- Geyer MA, Swerdlow NR, Mansbach RS, Braff DL (1990). Startle response models of sensorimotor gating and habituation deficits in schizophrenia. *Brain Res Bull* 25: 485–498.
- Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature* 379: 606–612.
- Giros B, Martres MP, Sokoloff P, Schwartz JC (1990). Gene cloning of human dopaminergic D₃ receptor and identification of its chromosome. *C R Acad Sci III* 311: 501–508.
- Glenhøj BY, Hemmingsen R (1997). Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 21: 23–46.
- Gross G, Bialoian S, Drescher K, Freeman A, Garcia-Ladona F, Hoger T *et al* (1997). Evaluation of D₃ receptor antagonists. *Eur Neuropsychopharmacol* 7: S120.
- Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P (2001). BDNF controls dopamine D₃ receptor expression and triggers behavioural sensitization. *Nature* 411: 86–89.
- Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN (1997). Mesolimbic dopamine D₃ receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. *Arch Gen Psychiatry* 54: 225–232.
- Gurevich EV, Joyce JN (1999). Distribution of dopamine D₃ receptor expressing neurons in the human forebrain:

- comparison with D2 receptor expressing neurons. *Neuropsychopharmacology* 20: 60–80.
- Howes OD, McDonald C, Cannon M, Arseneault L, Boydell J, Murray RM (2004). Pathways to schizophrenia: the impact of environmental factors. *Int J Neuropsychopharmacol* 7(Suppl 1): S7–S13.
- Janowsky DS, Davis JM (1976). Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. *Arch Gen Psychiatry* 33: 304–308.
- Joyce JN (2001). Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. *Pharmacol Ther* 90: 231–259.
- Kongsamut S (2003). *The Discovery and Development of Dopamine D3 Antagonists for the Treatment of Schizophrenia*. Psychiatric Drug Discovery & Development: Princeton, NJ.
- Kramer MS, Last B, Getson A, Reines SA (1997). The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. *Arch Gen Psychiatry* 54: 567–572.
- Le Pen G, Moreau JL (2002). Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. *Neuropsychopharmacology* 27: 1–11.
- Leriche L, Schwartz JC, Sokoloff P (2003). The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. *Neuropharmacology* 45: 174–181.
- Leysen JE, Janssen PM, Schotte A, Luyten WH, Megens AA (1993). Interaction of antipsychotic drugs with neurotransmitter receptor sites *in vitro* and *in vivo* in relation to pharmacological and clinical effects: role of 5HT2 receptors. *Psychopharmacology (Berl)* 112: S40–S54.
- Lieberman JA, Kane JM, Alvir J (1987). Provocative tests with psychostimulant drugs in schizophrenia. *Psychopharmacology (Berl)* 91: 415–433.
- Lieberman JA, Sheitman BB, Kinon BJ (1997). Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. *Neuropsychopharmacology* 17: 205–229.
- Lipska BK, Aultman JM, Verma A, Weinberger DR, Moghaddam B (2002). Neonatal damage of the ventral hippocampus impairs working memory in the rat. *Neuropsychopharmacology* 27: 47–54.
- Lipska BK, Jaskiw GE, Weinberger DR (1993). Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. *Neuropsychopharmacology* 9: 67–75.
- Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1995). Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. *Psychopharmacology (Berl)* 122: 35–43.
- Lipska BK, Weinberger DR (2000). To model a psychiatric disorder in animals: schizophrenia as a reality test. *Neuropsychopharmacology* 23: 223–239.
- Mansbach RS, Geyer MA (1989). Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. *Neuropsychopharmacology* 2: 299–308.
- Mansbach RS, Geyer MA, Braff DL (1988). Dopaminergic stimulation disrupts sensorimotor gating in the rat. *Psychopharmacology (Berl)* 94: 507–514.
- McCaughan Jr J, Mahjubi E, Decena E, Hitzemann R (1997). Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. *Psychopharmacology (Berl)* 134: 131–139.
- McGhie A, Chapman J (1961). Disorders of attention and perception in early schizophrenia. *Br J Med Psychol* 34: 103–116.
- Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M (2004). The role of dopamine D(3) compared with D(2) receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. *Psychopharmacology (Berl)* 174: 341–357.
- Mills A, Allet B, Bernard A, Chabert C, Brandt E, Cavegn C et al (1993). Expression and characterization of human D4 dopamine receptors in baculovirus-infected insect cells. *FEBS Lett* 320: 130–134.
- Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z et al (2001). The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? *Psychopharmacology (Berl)* 156: 284–290.
- Ouagazzal AM, Jenck F, Moreau JL (2001). Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? *Psychopharmacology (Berl)* 156: 273–283.
- Paxinos G, Watson C (1998). *The Rat Brain in Stereotaxic Coordinates*. Academic Press: San Diego, CA.
- Paylor R, Crawley JN (1997). Inbred strain differences in prepulse inhibition of the mouse startle response. *Psychopharmacology (Berl)* 132: 169–180.
- Peng RY, Mansbach RS, Braff DL, Geyer MA (1990). A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia. *Neuropsychopharmacology* 3: 211–218.
- Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG et al (1999). Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. *Nature* 400: 371–375.
- Pilon C, Levesque D, Dimitriadou V, Griffon N, Martres MP, Schwartz JC et al (1994). Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. *Eur J Pharmacol* 268: 129–139.
- Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G et al (1995). Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. *J Pharmacol Exp Ther* 275: 1355–1366.
- Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA (2001). Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. *J Neurosci* 21: 305–313.
- Ralph RJ, Varty GB, Kelly MA, Wang YM, Caron MG, Rubinstein M et al (1999). The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. *J Neurosci* 19: 4627–4633.
- Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY et al (2000). Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. *J Pharmacol Exp Ther* 294: 1154–1165.
- Richtand NM, Woods SC, Berger SP, Strakowski SM (2001). D3 dopamine receptor, behavioral sensitization, and psychosis. *Neurosci Biobehav Rev* 25: 427–443.
- Rueter LE, Ballard ME, Gallagher KB, Basso AM, Curzon P, Kohlhaas KL (2004). Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. *Psychopharmacology (Berl)* 176: 312–319.
- Sams-Dodd F, Lipska BK, Weinberger DR (1997). Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. *Psychopharmacology (Berl)* 132: 303–310.
- Schwartz JC, Diaz J, Pilon C, Sokoloff P (2000). Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. *Brain Res Brain Res Rev* 31: 277–287.

- Seeman P, Tallerico T (1998). Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. *Mol Psychiatry* 3: 123–134.
- Sipes TA, Geyer MA (1994). Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. *Neuropharmacology* 33: 441–448.
- Swerdlow NR, Geyer MA (1993). Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. *Pharmacol Biochem Behav* 44: 741–744.
- Swerdlow NR, Keith VA, Braff DL, Geyer MA (1991). Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. *J Pharmacol Exp Ther* 256: 530–536.
- Unger L, Garcia-Ladona F, Wermet W, Sokoloff P, Gross G (2002). *In vitro* characterization of the selective dopamine D3 receptor antagonist A-437203. 32th Annual Meeting, Society of Neuroscience, Orlando.
- Varty GB, Higgins GA (1998). Dopamine agonist-induced hypothermia and disruption of prepulse inhibition: evidence for a role of D3 receptors? *Behav Pharmacol* 9: 445–455.
- Vorel SR, Ashby Jr CR, Paul M, Liu X, Hayes R, Hagan JJ, Middlemiss DN, Stemp G, Gardner EL (2002). Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. *J Neurosci* 22: 9595–9603.
- Wan FJ, Taaid N, Swerdlow NR (1996a). Do D1/D2 interactions regulate prepulse inhibition in rats? *Neuropsychopharmacology* 14: 265–274.
- Wan RQ, Corbett R (1997). Enhancement of postsynaptic sensitivity to dopaminergic agonists induced by neonatal hippocampal lesions. *Neuropsychopharmacology* 16: 259–268.
- Wan RQ, Giovanni A, Kafka SH, Corbett R (1996b). Neonatal hippocampal lesions induced hyperresponsiveness to amphetamine: behavioral and *in vivo* microdialysis studies. *Behav Brain Res* 78: 211–223.
- Wicke K, Garcia-Ladona J (2001). The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. *Eur J Pharmacol* 424: 85–90.
- Wood MD, Boyfield I, Nash DJ, Jewitt FR, Avenell KY, Riley GJ (2000). Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. *Eur J Pharmacol* 407: 47–51.
- Zapata A, Witkin JM, Shippenberg TS (2001). Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses. *Neuropharmacology* 41: 351–359.
- Zhang M, Ballard ME, Drescher K, Gross G, Decker MW, Rueter LE (2003). Evaluation of D3 receptor involvement in psychosis: studies in preclinical animal models. 33th Annual Meeting, Society of Neuroscience, New Orleans.